The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
Transcript
The FDA recently approved the first immunotherapy regimen for breast cancer with the approval of atezolizumab. How important was this approval for a type of breast cancer that didn’t have many other treatment options?
We’re very excited about the approval of atezolizumab in triple-negative breast cancer. This is a disease that has a poor outcome, and of all the subgroups of breast cancer, this one has the worst prognosis when it becomes metastatic. And also, we’ve been very excited about immuno-oncology (IO) drugs in many other types of cancers.
We’ve been waiting in breast cancer to get an IO drug approved, and now we have atezolizumab with abraxane for triple-negative breast cancer patients that are PD-L1 [programmed death ligand-1] positive—that’s the biomarker that distinguishes those that are going to respond. We’ve seen some great results with response rates and some intriguing preliminary overall survival data, which will have to continue to mature. I think the breast cancer community is very excited about having an IO options finally to treat our patients, particularly for this very difficult group of patients to treat.
Do you think there is a future for more immunotherapy in breast cancer?
Yes—we’re going to be seeing many other trials of immunotherapy in breast cancer. In the metastatic setting, in the same type of setting that atezolizumab has been approved, there are other partner drugs that are being tested with atezolizumab. Some of the other PD-1 and PD-L1 inhibitors are also being tested in the first-line for metastatic disease, and we’ve already learned that PD-1 inhibitors in breast cancer work better the earlier that you use them before the immune system is exhausted. That’s led to studies of using immunotherapy in the neoadjuvant or adjuvant setting. Those studies are ongoing, but many of us are very excited that that might be the ultimate best use of immunotherapy in breast cancer and preventing recurrence of disease rather than treating it.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More